AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33051340
Drug: Pembrolizumab +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab + Traditional Radiation Therapy (45 Gy in 15 fractions)
Trial: 32838470
Drug: Non-vitamin K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-vitamin K dependent oral anticoagulants (NOACs)
Trial: 33677049
Drug: Whole-lung low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Whole-lung low-dose radiation therapy (LDRT) 1 Gy
Trial: 33677049
Drug: Whole-lung low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Whole-lung low-dose radiation therapy (LDRT)
Trial: 32067817
Drug: EV71 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EV71 vaccine from Institute of Medical Biology Chinese Academy of Medical Sciences (CAMS) for the first dose and Sinovac vaccine for the second dose (Group D)
Trial: 32067817
Drug: Single vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single vaccine from one manufacturer (two groups)
Trial: 32067817
Drug: Mixed schedules
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed schedules using vaccines from two manufacturers (two groups)
Trial: 35446282
Drug: Compound Training
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound Training (CPD)
Trial: 32268344
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg of haloperidol
Trial: 34187530
Drug: LPV (Vt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPV (Vt = 6 ml/kg of ideal body weight, respiratory rate initially set at 16 breaths/min, PEEP at 5 cmH2O, recruitment manoeuvre applied)
Trial: 34187530
Drug: Control (Vt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Vt = 10 ml/kg of ideal body weight, respiratory rate initially set at 6–8 breaths/min, no PEEP, no recruitment manoeuvre)
Trial: 33487255
Drug: DHA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA supplementation (650 mg DHA, 3 times/week, post-HD session)
Trial: 32507538
Drug: Cholecalciferol (vitamin
RxNorm normalized name: cholecalciferol (vitamin D3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol (vitamin D3) 4,000 IU or 7,000 IU daily for 6 and 12 weeks
Trial: 34397393
Drug: Internet-based warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based warfarin management
Trial: 34397393
Drug: Conventional warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional warfarin management
Trial: 36892753
Drug: Risankizumab 180
RxNorm normalized name: RISANKIZUMAB 180 mg in 1.2 mL SUBCUTANEOUS INJECTION, SOLUTION [Skyrizi]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risankizumab 180 mg
Trial: 35710572
Drug: Heterologous boost
RxNorm normalized name: BOOST
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heterologous boost COVID‐19 vaccine regimens (intervention groups 1–4)
Trial: 32721007
Drug: 0.625 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg/d of conjugated equine estrogen (CEE) alone
Trial: 32721007
Drug: 0.625 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg/d of conjugated equine estrogen (CEE) plus 2.5 mg/d of medroxyprogesterone acetate (MPA)
Trial: 35489363
Drug: Lenvatinib (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenvatinib (oral 20 mg per day) plus Pembrolizumab (intravenous 200 mg every 21 days)
Trial: 35489363
Drug: Sunitinib (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib (oral 50 mg per day, 4 weeks on followed by 2 weeks off)
Trial: 33942376
Drug: Inosine (active
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inosine (active treatment)
Trial: 33581174
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg MET409
Trial: 33581174
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg MET409
Trial: 32648183
Drug: Laparoscopic resection
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laparoscopic resection for rectal cancer
Trial: 32633541
Drug: All antipsychotics
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All antipsychotics combined
Trial: 35557513
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment group (CDDP 20 pills three times per day)
Trial: 35557513
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment group (10 pills CDDP and 10 pills placebo three times per day)
Trial: 33059380
Drug: Topical anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anaesthesia with 0.5% tetracaine-HCl ophthalmic solution applied three times at 30-second intervals after wound closure
Trial: 33059380
Drug: No topical
RxNorm normalized name: Altreno Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No topical anaesthesia (control group)
Trial: 35144570
Drug: Inquiry‐Based Stress
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inquiry‐Based Stress Reduction counseling session (2 hours weekly for 6 weeks)
Trial: 33244872
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) alpha1‐PI[h] therapy (90 or 180 mg/kg weekly for 13 or 26 weeks)
Trial: 33244872
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) alpha1‐PI[h] therapy
Trial: 35841457
Drug: Mongersen (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mongersen (oral antisense oligonucleotide targeting Smad7)
Trial: 35077474
Drug: rasagiline (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rasagiline (1 mg/day)
Trial: 35077474
Drug: rasagiline (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rasagiline (0.5 mg/day)
Trial: 33757474
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose cranberry proanthocyanidin extract (2 × 18.5 mg daily, n = 72)
Trial: 33757474
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose cranberry proanthocyanidin extract (2 × 1 mg daily, n = 73)
Trial: 33757474
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose cranberry proanthocyanidin extract
Trial: 32833477
Drug: Mindfulness based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness based cognitive therapy ‐ perinatal depression (MBCT‐PD)
Trial: 35139937
Drug: Platelet-rich plasma
RxNorm normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-rich plasma gel
Trial: 36319057
Drug: Methenamine hippurate
RxNorm normalized name: Methenamine Hippurate
DrugBank: Methenamine (DB06799)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methenamine hippurate 1 g, two times per day for 6 months
Trial: 36319057
Drug: Placebo tablets,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets, two times per day for 6 months
Trial: 33109586
Drug: α-type-1 DC
RxNorm normalized name: WHITE SPIRIT TYPE 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: α-type-1 DC vaccine
Trial: 32245508
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (HCQ) for 4 weeks in the START block, followed by a switch to active drug for the placebo group.
Trial: 37246674
Drug: Same Arm
RxNorm normalized name: SAMe
DrugBank: Ademetionine (DB00118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same Arm Movement Therapy for 8 weeks (45 min supervised sessions 3 times a week and structured independent sessions twice a week)
Trial: 37246674
Drug: Constraint Induced
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constraint Induced Movement Therapy for 8 weeks (2 hours per day, 5 days a week, with restriction of the non-affected extremity for 10 hours a day)
Trial: 32532583
Drug: Intravenous adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous adenosine triphosphate (ATP) infusion at 210 μg/kg/min (IVATP210)
Trial: 32532583
Drug: Intravenous adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous adenosine triphosphate (ATP) infusion at 150 μg/kg/min (IVATP150)
Trial: 32532583
Drug: Intracoronary administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary administration of nicorandil 2 mg (ICNIC2mg)
Trial: 32304185
Drug: Relaxation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relaxation therapy (RT) and information only (Co)
Trial: 32304185
Drug: Supplementary treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplementary treatment (ST)
Trial: 36424550
Drug: Intervention (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention (daily automated flags in CHORUS™)
Trial: 32660748
Drug: Atezolizumab vs
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab vs Chemotherapy
Trial: 33513242
Drug: Neutralizing antibodies
RxNorm normalized name: DentiCare Neutral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutralizing antibodies (Nabs) measured using a lentiviral vector‐based SARS‐CoV‐2 neutralization assay
Trial: 33513242
Drug: Neutralizing antibodies
RxNorm normalized name: DentiCare Neutral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutralizing antibodies (Nabs) in patients with diabetes
Trial: 33950945
Drug: Placebo acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo acupuncture (placebo treatment using a similarly designed press tack needle without the needle element)
Trial: 35305222
Drug: CBT4CBT‐Spanish (culturally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBT4CBT‐Spanish (culturally adapted Spanish‐language version of web‐based cognitive behavioral therapy)
Trial: 34489516
Drug: Nurse-led, telephone-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nurse-led, telephone-based follow-up including medical titration
Trial: 33236646
Drug: SIC +
RxNorm normalized name: TRACH CANNULA,SZ 8 SHLY #8-SIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SIC + Octagam (30 g/day for 5 days)
Trial: 35143095
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (thrombectomy preceded by intravenous alteplase)
Trial: 34735963
Drug: Perampanel (PER)
RxNorm normalized name: Perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Perampanel (PER) at doses of 8 mg and 12 mg/day
Trial: 34735963
Drug: Perampanel (PER)
RxNorm normalized name: Perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Perampanel (PER) at doses of 2 mg and 4 mg/day
Trial: 32311925
Drug: Photobiomodulation (PBM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photobiomodulation (PBM) treatment with a diode laser emitting at 808 nm, 100 mW, for 40 seconds per site, 20 sites irradiated weekly for 4 weeks
Trial: 32311925
Drug: Placebo PBM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo PBM treatment
Trial: 35460304
Drug: Photobiomodulation (PBM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photobiomodulation (PBM) in addition to conventional symptomatic treatment
Trial: 34618482
Drug: Physical and/or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical and/or sexual abuse treatment (PSA‐T)
Trial: 32596729
Drug: Potassium supplement
RxNorm normalized name: Potassium supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium supplement (90 mmol/day)
Trial: 32184185
Drug: Minesapride 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minesapride 40 mg
Trial: 32087003
Drug: Minesapride 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minesapride 120 mg
Trial: 35829629
Drug: Chemotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy and radiation therapy
Trial: 35477634
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) ketamine (0.5 mg/kg, infused over 40 minutes)
Trial: 35477634
Drug: Intranasal (IN)
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal (IN) esketamine (56/84 mg)
Trial: 32303436
Drug: Edetate disodium
RxNorm normalized name: Edetate Disodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edetate disodium chelation therapy (40 infusions of a 500 mL solution)
Trial: 33472420
Drug: Web ORLA®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web ORLA® (Oral Reading for Language in Aphasia)
Trial: 32537276
Drug: Conventional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional physical therapy with visceral mobilization
Trial: 34265777
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy for Insomnia (CBTi) followed by Cognitive Processing Therapy (CPT)
Trial: 35430325
Drug: Theta tACS
RxNorm normalized name: Coptis teeta root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theta tACS (20 minutes) during daily multitasking training
Trial: 35430325
Drug: Delta tACS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delta tACS (20 minutes) during daily multitasking training
Trial: 35175905
Drug: 6-month all-oral
RxNorm normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-month all-oral regimen including levofloxacin, bedaquiline, and linezolid
Trial: 32001833
Drug: Intraperitoneal carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intraperitoneal carboplatin (AUC = 6) and intravenous paclitaxel (80 mg/m2) administered on days 1, 8, and 15.
Trial: 32713466
Drug: Intravenous TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous TXA (single preoperative dose)
Trial: 33310052
Drug: Progressive relaxation
RxNorm normalized name: Relax-DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progressive relaxation exercises (self-administered via CD for two menstrual cycles)
Trial: 32209248
Drug: MenACYW-TT co-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenACYW-TT co-administered with Tdap and HPV4
Trial: 32209248
Drug: Tdap and
RxNorm normalized name: metformin and ertugliflozin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tdap and HPV4 vaccines alone
Trial: 34617974
Drug: Lifitegrast ophthalmic
RxNorm normalized name: lifitegrast ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lifitegrast ophthalmic solution, 5.0%, twice daily for 84 days
Trial: 33480963
Drug: Margetuximab (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Margetuximab (15 mg/kg) plus chemotherapy
Trial: 33480963
Drug: Trastuzumab (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab (6 mg/kg, loading dose 8 mg/kg) plus chemotherapy
Trial: 34907910
Drug: Atezolizumab plus
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab plus cobimetinib (combination arm)
Trial: 34907910
Drug: Atezolizumab monotherapy
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab monotherapy (monotherapy arm)
Trial: 32941462
Drug: Proactive electronic-consultation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proactive electronic-consultation from pulmonologists recommending ICS discontinuation
Trial: 32941462
Drug: Unexposed providers'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unexposed providers' anticipation of patient resistance to ICS discontinuation
Trial: 33836161
Drug: Benznidazole 300
RxNorm normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benznidazole 300 mg daily for 8 weeks
Trial: 33836161
Drug: Benznidazole 300
RxNorm normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benznidazole 300 mg daily for 4 weeks
Trial: 33836161
Drug: Benznidazole 300
RxNorm normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benznidazole 300 mg daily for 2 weeks
Trial: 33836161
Drug: Benznidazole 150
RxNorm normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benznidazole 150 mg daily for 4 weeks
Trial: 33836161
Drug: Benznidazole 150
RxNorm normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benznidazole 150 mg daily for 4 weeks plus fosravuconazole
Trial: 33836161
Drug: Benznidazole 300
RxNorm normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benznidazole 300 mg weekly for 8 weeks plus fosravuconazole
Trial: 616864697
Drug: Mannatide, oxaliplatin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mannatide, oxaliplatin, and docetaxel sequential therapy
Trial: 616864697
Drug: Thymosin, oxaliplatin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymosin, oxaliplatin, and docetaxel sequential therapy
Trial: 34526081
Drug: Raw natural
RxNorm normalized name: raw sugar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raw natural honey (0.5 g) and encapsulated organic Nigella sativa seeds (40 mg) per kg body weight per day
Trial: 34526081
Drug: Placebo (empty
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (empty capsule with 30 ml of 5% dextrose water)
Trial: 36206399
Drug: Therapy duration
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy duration >= 1 year
Trial: 32282564
Drug: Acupressure on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupressure on 6 acupoints administered at home every night for 4 weeks
Trial: 32282564
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group maintained their daily routine
Trial: 34781981
Drug: Hydroxychloroquine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (400 mg daily for the first four days, then 400 mg weekly)
Trial: 34781981
Drug: Placebo (same
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (same treatment schedule as hydroxychloroquine)
Trial: 33579340
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (neoadjuvant radiotherapy + surgery)
Trial: 33749976
Drug: Adherence to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adherence to biological metrics of Life's Simple 7 (LS7)
Trial: 32221084
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese medicine combined with western medicine (ESWL treatment and TCM therapy)
Trial: 32221084
Drug: Conventional drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional drug treatment (control group)
Trial: 34985309
Drug: Standard-dose DOAC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose DOAC
Trial: 34985309
Drug: Lower-dose DOAC
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower-dose DOAC
Trial: 33528930
Drug: Subcutaneous immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous immunotherapy with allergens (SCITA)
Trial: 35435087
Drug: Plasma gel
RxNorm normalized name: Plasma gelsolin
DrugBank: Recombinant human plasma gelsolin (DB15746)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma gel
Trial: 35435087
Drug: Control (Plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Plasma gel vs Plasma fluid)
Trial: 32758407
Drug: Sternotomy group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sternotomy group (15 patients) received 0.25% bupivacaine subcutaneous infiltration.
Trial: 32758407
Drug: Thoracotomy group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracotomy group (15 patients) with 11 receiving fascial plane block and 3 receiving subcutaneous infiltration.
Trial: 33049433
Drug: Clinical judgment
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical judgment (recommended treatment)
Trial: 34874888
Drug: blended cognitive
RxNorm normalized name: Io-Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: blended cognitive behavioral therapy (bCBT)